Novo Nordisk is suing Eli Lilly in U.S. federal court for false advertising, alleging misleading claims about its weight-loss drugs. Novo seeks to block Lilly’s ads and requires corrective measures, citing violations of federal and state laws amid misleading comparisons of drug efficacy.
About the Author
